Registration

The following registration fees and deadlines apply for ANZCHOG ASM 2022.

Registration rates

EARLY
before 27/05/2022
STANDARD
after 27/05/2022
ONSITE
from 28/07/2022
Full ASM delegate
650 AUD
790 AUD
850 AUD
Full ASM consumer
500 AUD
560 AUD
620 AUD

Pre-ASM nursing workshop included with full registration. Registration rate for workshop only to be determined.

Inclusions

FULL ASM DELEGATE

FROM  650
AUD
  • Access to all scientific sessions
  • Access to exhibition and poster displays
  • Morning/afternoon teas and lunches as per the program
  • 1x ticket to the welcome reception on Thursday 28 July
  • 1x ticket to the gala dinner on Friday 29 July
  • Option to pre-ASM nursing workshop*

* Space for the pre-ASM nursing workshop is limited, you will need to indicate during the registration process if you would like to attend.

FULL ASM CONSUMER

FROM  500
AUD
  • Access to all scientific sessions
  • Access to exhibition and poster displays
  • Morning/afternoon teas and lunches as per the program
  • 1x ticket to the welcome reception on Thursday 28 July

CONSUMER – A patient/parent/carer or similar who works in a volunteer capacity in the paediatric oncology space, or consumer representatives from other charities/philanthropy groups including parent groups or similar. ANZCHOG adheres to the COSA Cancer Cooperative Trials Group guidelines, which recommends consumers attending a Scientific Meeting are trained experts who should be differentiated from the general public.

Parent program registration

You will have the option to register your attendance to the Parent Program during the registration process for the ASM.

If you would like to attend the virtual Parent Program only please proceed via the standard registration portal and use registration code*: PAR22 when prompted in order to bypass the ASM registration.

*Please note, by using this code, you will not be registered to attend the ASM or any of the social functions.

Example

FAQ

Early bird registrations will be accepted until Friday 27 May 2022 midnight AEST.
Should your registration remain unpaid on Monday 13 June 2022, your registration fees will be updated to the standard registration fee.

As of Saturday 28 May 2022, standard registration fees apply for every new registration.
Should your registration remain unpaid on Wednesday 27 of July 2022, your registration fees will be updated to the onsite registration fee.

From Thursday 28 July 2022 & onsite, onsite registration fee applies for every new registration.

The health and safety of our delegates is our utmost priority and we recognise that delegates may need to cancel due to unforeseen circumstances. We will review your request on a case by case basis and in some instances, you may be asked for additional details.

For further information on how your data will be used, we invite you to carefully read the Data Protection and Privacy Policy: https://www.wearemci.com/en-au/privacy-statement

Insurance, release and waiver of liability:

It is recommended that participants obtain adequate cover for travel, health and accident insurance before they depart from their countries. ANZCHOG and MCI as organisers cannot accept responsibility for personal injuries, or loss of, or damage to, private property belonging to the Conference participants and
accompanying persons. Participants are requested to inform themselves and to abide by local work regulations accordingly.

ACEM, MCI, and Venue are not responsible for either the partial or total non-execution of the contract in the event of accident, natural disaster (either threatened or actual), in war,curtailment or interruption of transportation facilities, threats or acts of terrorism, of transportation facilities, threats or acts of
terrorism, governmental travel or terrorism advisory, Strikes, Lock out, civil disturbance, the issue of a Travel Warning by the World Health Organisation or any other cause beyond the parties’ control which prevents the venue from accommodating the clients of MCI for the event or if for the same reasons the event is cancelled by MCI. The Organisers may at their entire discretion repay the delegate fee or Service Charge paid by the Delegate or Exhibitor, or part thereof, but shall be under no obligation to repay the whole or part of such Delegate fee or Service Charge, and shall be under no liability to the Delegate or Exhibitor in respect of any actions, claims, losses (including consequential losses), costs or expenses whatsoever which may be brought against or suffered or incurred by the Delegate or Exhibitor, as the result of the happening of any such event.

Minimum age:

Registration and/or admittance to the Conference shall be limited solely to participants who are 18 years of age or older, due to current health and safety regulations and legislation in effect.

Any registration by anyone who is under 18 is unauthorised and in violation of these Terms and Conditions and will automatically result in the forfeit of their registration. You hereby accept that identification is to be provided to Conference staff upon request.

By registering to the Conference or entering the Conference you represent and warrant that you are 18 years of age or older, and that you agree to and to abide by all of the Terms and Conditions of this Conference.

Force majeure:

ANZCHOG and MCI are not responsible for either the partial or total non-execution of the contract in the event of accident, an act caused by a third party, such as Acts of God including, without limitation, credible threats of natural disaster in the geographic vicinity, war, curtailment or interruption of transportation facilities, threats or acts of terrorism or similar acts, governmental travel advisory, a governmental elevation of the terrorism alert level, civil disturbance, the issue of a Travel Warning by the World Health Organisation or any other cause comparable events or disaster beyond the parties’ control which prevents the Venue
from accommodating the clients of MCI for the event or if for the same reasons the event is cancelled by MCI.

Photography/Videography Disclosure:

As a registered attendee of the Conference, you agree to grant permission for ANZCHOG and MCI to use your likeness in a photograph or video in any and all of its publications and presentations, including website entries, without payment or any other consideration;to authorise ANZCHOG and MCI to edit, alter, copy, exhibit, publish or distribute the photograph or video for purposes of publicising ANZCHOG programs or for any other lawful purpose; to waive the right to inspect or approve the finished product, including written or electronic copy, wherein your likeness appears; that these materials will become the property of ANZCHOG and MCI.

Visa:

Please visit the following website http://visahq.com/ to check if you require a visa for Australia. Citizens of other countries may need a visa. Please contact your travel agent or the nearest Australiadiplomatic authorities for further information. If you should need a visa, please apply early enough to allow sufficient handling time to the authorities.

During the reservation process, please tick the box and fill in the corresponding questionnaire in order to receive your Visa invitation letter. Please note that the VISA invitation letter will only be sent to participants who have paid their reservation fee.

Please note that neither ANZCHOG nor MCI will be able to contact or intervene with any Embassy or Consulate office on behalf of a registrant. The invitation letter does not financially or legally obligate ANZCHOG or MCI in any way. All expenses incurred in relation to the event and to obtaining a visa are the sole responsibility of the registrant. ANZCHOG and MCI do not accept any responsibility for travel, accommodation and/or other costs incurred due to the rejection of a registrant’s visa application.

Jazz Pharmaceuticals is a global Biopharmaceutical Company whose purpose is to transform the lives of patients and their families through innovation. We are dedicated to developing life-changing medicines for people with serious diseases—often with limited or no therapeutic options so they can live their lives more fully.

We have a diverse portfolio of marketed medicines and novel product candidates, from early- to latestage development, in Neuroscience and Haematology/Oncology. Within these therapeutic areas, we are identifying new options for patients by actively exploring small molecules and biologics, and through innovative delivery technologies and cannabinoid science.

Jazz Pharmaceuticals has employees around the globe including Australia and New Zealand, serving patients in nearly 75 countries

Medical Information
Phone: 1800577422
Email: medinfo-apac@jazzpharma.com

Adverse event
Phone: 1800577422
Email: AEReporting@jazzpharma.com


To report a Product Complaint, please email:
productcomplaints@jazzpharma.com

Dr Robert Battisti

Children’s Hospital Westmead

Dr Battisti is a Clinical Psychologist and Researcher at the Cancer Centre for Children at the Children’s Hospital at Westmead, and an Honorary Research Associate at the University of Sydney. Dr Battisti completed his PhD at the University of Wollongong and a postdoctoral position with the National Drug and Alcohol Research Centre (NDARC) at the University of New South Wales in partnership with the Brain and Mind Centre at the University of Sydney. Dr Battisti is also on the Board of Directors for the Australian Clinical Psychology Association (ACPA). His clinical background is in child, adolescent and young adult (AYA) psychology as well as parenting psychology, with expertise in paediatric cancer including childhood cancer survivorship.

A/Prof Antoinette Anazodo

Kids Cancer Centre, Sydney Children’s Hospital

A/Professor Anazodo is the lead clinician for Youth Cancer Services in NSW and the ACT, and the Director of the Adolescent and Young Adult Cancer Service encompassing Sydney Children’s Hospital and Prince of Wales Hospital. She leads the Future Fertility research program and has been instrumental in making fertility preservation accessible for oncology patients all around Australia, by developing Medicare item numbers for public funding. A/Professor Anazodo chairs the Australian AYA fertility preservation group, which leads the development of guidelines in the field of oncofertility. She has over 100 publications in the fields of adolescent medicine and oncofertility, and is a principle investigator on multiple successful grants from both the NHMRC and Cancer Australia. A/Professor Anazodo has received a number of awards for her work including a NSW Premiers award in 2018 and a Medal of the Order of Australia in 2021.

Dr Justin Baker

St Jude Children’s Research Hospital

Dr Baker is the Division Chief of Quality of Life and Palliative Care at St. Jude Children’s Research Hospital, Memphis, TN, USA. He is trained in paediatric haematology/oncology, as well as Hospice and Palliative Medicine. Dr Baker is a world leader in paediatric palliative care and quality of life, with over 100 publications in the field. His research focuses on integrating palliative care into the ongoing care of children with cancer, the ethical consideration of early phase trials, and paediatric palliative care in developing countries. He was awarded the AAHPM Inspirational Leader in Hospice and Palliative Medicine in 2014, and the St. Jude Communicator of the Year in 2017. Dr Baker has led the development of guidelines in paediatric palliative care and quality of life that have been implemented in centres throughout the world, and has been an invited speaker at paediatric oncology and palliative care conferences across the globe.

Dr Robert Battisti

Children’s Hospital Westmead

Dr Battisti is a Clinical Psychologist and Researcher at the Cancer Centre for Children at the Children’s Hospital at Westmead, and an Honorary Research Associate at the University of Sydney. Dr Battisti completed his PhD at the University of Wollongong and a postdoctoral position with the National Drug and Alcohol Research Centre (NDARC) at the University of New South Wales in partnership with the Brain and Mind Centre at the University of Sydney. Dr Battisti is also on the Board of Directors for the Australian Clinical Psychology Association (ACPA). His clinical background is in child, adolescent and young adult (AYA) psychology as well as parenting psychology, with expertise in paediatric cancer including childhood cancer survivorship.

Prof Paul Monagle

University of Melbourne

Professor Monagle is an internationally renowned paediatric haematologist and haemato-pathologist. He is a Professor of Paediatrics at the University of Melbourne, a clinical Haematologist at the Kids Cancer Centre, Sydney Children’s Hospital, and an Honorary Fellow and Group Leader in Haematology Research at the Murdoch Children’s Research Institute. Professor Monagle is a world expert on thrombosis and coagulation, with over 300 publications in the field of paediatric haematology. His research group holds multiple NHMRC grants and is currently leading work into COVID-19 associated thrombosis. Professor Monagle was awarded the Outstanding Research Award in Paediatric Cardiology by the American Heart Association in 2008, and delivered the Barry Firkin Oration for the Thrombosis & Haemostasis Society of Australia and New Zealand in 2018. He has played a key role in designing multiple international multi-centre trials, and been an invited speaker at haematology conferences across the globe.

Prof Marcus Vowels

Professor Vowels is a renowned early leader of the paediatric oncology and haematology disciplines in Australia. Professor Vowels established the first bone marrow transplant program in Australia at the then Prince of Wales Children’s Hospital, now Sydney Children’s Hospital in Randwick, NSW. Professor Vowels established the Australian Cord Blood Bank and was a founding trustee of the Australian Cord Blood Foundation. Professor Vowels has over 100 peer reviewed publications, he was the founding member of a number of editorial boards of discipline specific journals and is the author of multiple book chapters. Professor Vowels was the President of the Australian and New Zealand Children’s Cancer Study Group from 1990 to 1994, and was awarded a Member of the Order of Australia (AM) for his service to medicine, particularly in the fields of childhood leukaemia and cancer.

Annabel Crabb

ABC Journalist

Annabel Crabb is one of Australia’s most beloved journalists. She is an ABC writer and presenter who has covered Australian politics for 20 years but also is nationally well-known for her insightful and humorous analysis on gender and current affairs. 

Annabel recently created and presented the ground breaking Ms Represented, unearthing stories from the 100 years of women in Australian parliaments. For the ABC, she has also devised and presented six seasons of the enormously popular Kitchen Cabinet, and “The House with Annabel Crabb – the fly-on-the-wall documentary on Australian Parliament.” She also presents the ABC’s hit culinary history series Back In Time For Dinner, and co-stars in Tomorrow Tonight with Charlie Pickering.

With friend and ABC colleague Leigh Sales, Australia’s pre-eminent current affairs journalist, Annabel hosts the top-rating podcast Chat 10 Looks 3. Their first book together, Well Hello, was published in September 2021.

Annabel is an avid baker and proud mother of three.

Bayer is a global enterprise with core competencies in healthcare and agriculture. Through science and innovation, the company is committed to the lives of people impacted by cancer. Bayer’s oncology research prioritises cutting-edge science across a range of therapeutic platforms to give patients and clinicians a multitude of options in the fight against cancer.

For more than 20 years, Illumina has aspired to improve human health by unlocking the power of the genome. As we move towards precision medicinein pediatric cancer, we have only just begun to discover the true impact of genomics. Learn how Illumina technologies is enabling novel insights into childhood cancer risk and treatment. Visit: https://sapac.illumina.com/destination/Precision-Medicine-in-Pediatric-Cancers.html

We are a dynamic, global biopharmaceutical company focused on oncology and rare disease, continuously striving to confront gaps in patient care. EUSA Pharma is committed to deliver solutions that can have a meaningful effect on life, helping patients across a range of therapy areas. We are continuously looking for new opportunities to confront current gaps in patient care. Our ambition and entrepreneurial culture drive us to explore, acquire and in-license products that we believe can bring about real change for patients.

Servier is a privately owned pharmaceutical company, governed by a non-profit foundation that is committed to therapeutic progress to serve patient needs. Servier has a long-standing commitment to research and development.

Worldwide approximately 25% of branded product turnover is reinvested into research and development through the Servier Foundation, with half of that investment dedicated to research to help fight cancer.

Servier has significant investment in new products in early development in the areas of Oncology and Haematology with broad research and development platforms in cancer cell apoptosis and immuno-oncology. Servier Australia is also home to the Asia-Pacific clinical trial hub.

Servier is proud to support innovative partnering programs with world class institutions including WEHI in Australia to further advance scientific understanding in the area of oncology

Information coming soon.

The Robert Connor Dawes (RCD) Foundation was created in June 2013 in the memory of Robert ‘Connor Dawes’ who lost his 16-month battle with an ependymoma brain tumour at just 18 years of age. The RCD Foundation works to support brain matters projects in the areas of research, care and development – to fund the science to fight paediatric brain cancer and support patients in the meantime.

The Foundation operates in Australia and the US, and to date has invested $3.45M into paediatric brain cancer research, funding basic science and translational projects, as well as capacity building grants through fellowships, scholarships and travel grants. It has also leveraged another $10M, leading collaborative research initiatives. In addition to funding and partnering with Australian research institutes and Foundations, RCD is also active member of the Child’s Brain Tumour Network (CBTN), Paediatric Neuro-Oncology Consortium (PNOC) and the Collaborative Ependymoma Research Network (CERN). We leverage our research investments through partnering with like-minded and passionate organisations to continue to battle paediatric brain cancer.

Our history
The Kids’ Cancer Project is an independent national charity supporting childhood cancer research. Since 1993, the charity has contributed more than $50 million dollars to scientific research projects to help children with many different types of cancer.

Our Goal
Mission: To support bold scientific research that has the greatest chance of clinical success in the improvement of treatments of childhood cancers.

Vision: One hundred per cent survival for children with cancer while eradicating the harmful impacts treatment can bring.

What we stand for
Science: We believe the only way to improve outcomes for kids with cancer is through advances in medical research.

Solutions: Our research priorities reflect our focus on finding better treatments, building research capabilities and supporting survivorship programs.

Survival: Our founder, Col Reynolds OAM, made a promise
to never give up until a cure is found.

Information coming soon.

Information coming soon.

Join the ANZCHOG ASM mailing list

Stay informed with the latest updates
* indicates required